Follow us on Twitter
twitter icon@FreshPatents


Tetrahydrocannabinol patents

      

This page is updated frequently with new Tetrahydrocannabinol-related patent applications.




 Cannabis plant named 'midnight' patent thumbnailCannabis plant named 'midnight'
The disclosure relates to a new and distinct cannabis sativa l. Plant named ‘midnight’, having an almost equal ratio of cannabidiol (cbd) concentration to tetrahydrocannabinol (thc) concentration, (e.g., substantially close to 1), as illustrated and described herein..

 Cannabis plant named 'avidekel' patent thumbnailCannabis plant named 'avidekel'
The disclosure relates to a new and distinct cultivar of cannabis sativa plant named ‘avidekel’, characterized by a high amount of cannabidiol (cbd) (16.3%) and a very low amount of tetrahydrocannabinol (thc, 0.8%).. .

 Enkephalin-influencing composition and method patent thumbnailEnkephalin-influencing composition and method
A composition which includes phenylalanine, serine, glutamine and gaba (γ-aminobutyric acid). The composition contains the essential amino acids phenylalanine; glutamine; the non-essential amino acid serine; and gaba (γ-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin.
Bioadatp, Llc


 Apparatus and methods for biosynthetic production of cannabinoids patent thumbnailApparatus and methods for biosynthetic production of cannabinoids
The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) and cannabichromenic acid (cbca) in different ratios. The apparatus comprises: (i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (cbga), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) or cannabidiolic acid (cbda) and cannabichromenic acid..
Full Spectrum Laboratories Limited


 Cannabis separation patent thumbnailCannabis separation
Provided are a cannabis composition in pellet form, a method of preparing a cannabis composition in pellet form, a method of separating a plant resin from a harvested plant material, a method of treatment with a cannabis composition in pellet form, and a kit including a cannabis composition in pellet form. For example, the cannabis composition in pellet form may include a cannabinoid resin.

 Cannabis pellets patent thumbnailCannabis pellets
A cannabis composition in pellet form, a method of preparing a cannabis composition in pellet form, a method of separating a plant resin from a harvested plant material, a method of treatment with a cannabis composition in pellet form, and a kit including a cannabis composition in pellet form are provided. The cannabis composition in pellet form may include a cannabinoid resin.

 Composition of olivetol and  use to reduce or inhibit the effects of tetrahydrocannabinol in the human body patent thumbnailComposition of olivetol and use to reduce or inhibit the effects of tetrahydrocannabinol in the human body
Embodiments of the present invention relate to the use of a therapeutically-effective amount of olivetol to reduce, eliminate, inhibit or alleviate the psychoactive effects of thc in users of cannabis. Further embodiments of the present invention relate to a softgel, tablet or capsule of olivetol in combination with an edible oil..

 Composition of olivetol and  use to reduce or inhibit the effects of tetrahydrocannabinol in the human body patent thumbnailComposition of olivetol and use to reduce or inhibit the effects of tetrahydrocannabinol in the human body
Embodiments of the present invention relate to the use of a therapeutically-effective amount of olivetol to reduce, eliminate, inhibit or alleviate the psychoactive effects of thc in users of cannabis. Further embodiments of the present invention relate to a softgel, tablet or capsule of olivetol in combination with an edible oil..

 Method for making coffee products containing cannabis ingredients patent thumbnailMethod for making coffee products containing cannabis ingredients
The present disclosure is directed to methods of making a coffee products containing cannabinoids that are extracted from cannabis plant. According to one embodiment, the method includes the steps of (a) extracting cannabinoids from cannabis plant; and (b) admixing the cannabinoids into a coffee product.

 Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same patent thumbnailProdrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
Described herein are Δ9-thc prodrugs, methods of making Δ9-thc prodrugs, formulations comprising Δ9-thc prodrugs and methods of using Δ9-thc. One embodiment described herein relates to the transdermal administration of a Δ9-thc prodrug for treating and preventing diseases and/or disorders..
Zynerba Pharmaceuticals, Inc.


Method and system for extracting compounds from plants and plant based materials

The invention provides a method and system for extracting desired compounds from a plant or a plant based material featuring a) providing a plant or plant based material; b) pumping co2 gas from a co2 storage vessel into an apparatus containing a co2 circulation loop; c) circulating co2 through the plant or plant based material in the circulation loop; d) extracting the desired compounds; and e) discharging the co2 gas from the co2 circulation loop. The circulation loop may have a separator vessel and an extractor vessel, the desired compound may be a terpene, tetrahydrocannabinol (thc) or carbenoxolone (cbx), and the co2 may be circulated as a supercritical co2.
Mrx Xtractors Llc

Ultrapure tetrahydrocannabinol-11-oic-acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Ultrapure tetrahydrocannabinol-11-oic acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Ultrapure tetrahydrocannabinol-11-oic acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Cannabinoid composition and treating pain

A combination of thc, cbd and cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as shea butter cream to relieve pain. The thc and cbd mixture is extracted from a cannabis indica dominant strain using high pressure and carbon dioxide (co2) as a solvent and comprises: tetrahydrocannabinol “thc” (9-tetrahydrocannabinol (delta-9 thc), 8-tetrahydrocannabinol (delta-8 thc) and 9-thc acid), cannabidiol “cbd”, cannabinol “cbn”, cannabichromene (“cbc”), cannabigerol (“cbg”), terpenoids and flavonoids.
India Globalization Capital, Inc.

Compositions, dosages, and methods of using tetrahydrocannabinol derivatives

Dosage forms of compounds of formula i, e.g., ajulemic acid, and methods of delivering these compounds and using these compounds to treat or prevent a cb1/cb2 associated disease are disclosed.. .
Corbus Pharmaceuticals, Inc.

Method for increasing cannabinol content in a lipid-based extract of cannabis

A method for modifying cannabinol (cbn) to trans-Δ9-tetrahydrocannabinol (thc) content in a lipid-based extract of cannabis to yield a low-thc product. The method includes providing a lipid-based extract of cannabis containing thc, heating the lipid-based extract at 1 atm of pressure to 157 to 160° c.
Raderman Holdings, Llc

Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof.
Noramco, Inc.

Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof.
Noramco, Inc.

Anti-microbial composition comprising cannabinoids

This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities.
Axim Biotechnologies, Inc.

Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions..
Corbus Pharmaceuticals Inc.

Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis

The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (cbd) or cannabidivarin (cbdv) and delta-9-tetrahydrocannabinol (thc) or tetrahydrocannabinovarin (thcv).
Gw Pharma Limited

Apparatus and methods for biosynthetic production of cannabinoids

The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) and cannabichromenic acid (cbca) in different ratios. The apparatus comprises:(i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (cbga), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) or cannabidiolic acid (cbda) and cannabichromenic acid..
Full Spectrum Laboratories Limited

Process to extract and purify delta-9-tetrahydrocannabinol

Δ9-thc acid is extracted from cannabis flowers using a first organic solvent, then separated using a second aqueous solvent. Δ9-thc acid is converted to Δ9-thc carboxylic salt before being extracted by a third organic solvent and converted back to Δ9-thc carboxylic acid.
Axim Biotechnologies, Inc.

Uses of cannabidiol for treatment of infantile spasms

In some aspects, the invention relates to a method of treating or preventing infantile spasms in a subject, comprising administering to the subject a composition comprising cannabidiol (“cbd”). In certain preferred embodiments, the composition comprising cbd is substantially devoid of tetrahydrocannabinol (“thc”)..

Axillary transdermal compound delivery system

A deodorant stick drug delivery system has one or more hydrophilic carriers, water, one or more gelling agents, an active ingredient, and a solvent. The active ingredient may be cannabinoids, nicotine, caffeine, vitamins, insulin and tetrahydrocannabinol.

Composition with pharmacological effect for vaporizing and method

A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor.

Compressed tablet containing delta 9-tetrahydrocannabinol, its manufacture and use of such tablet in oral treatment

The present invention relates to compressed tablets for peroral delivery of the cannabinoid Δ9-tetrahydrocannabinol (thc). More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment 30-90 wt % of a granulate; 10-70 wt % of lactose; and 0-30 wt % of other tablet excipients; wherein the granulate contains: a.
Echo Pharmaceuticals B.v.

Methods for purifying trans-(-)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9 tetrahydrocannabinol

Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol.
Svc Pharma Lp

Novel fertilizer

The present invention is directed to a fertilizer composition comprising a cannabidiol (cbd oil), and/or a tetrahydrocannabinol (thc oil) and/or hemp oil derivatives in combination with a superabsorbent polymer(s) (sap's). The present invention also relates to methods of using and manufacturing said fertilizers..

Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol

Methods for making trans-(−)-Δ9-tetrahydrocannabinoi and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinoi composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol.

Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol

Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol.

System and determining a concentration of a compound in a solvent

The present describes a system and method for determining the concentration of tetrahydrocannabinol (thc) including a tray comprising a first analyte including an infusion of a solvent and cannabis, a light emitting element configured to illuminate the first analyte, a light receiving element configured to receive a first light transmitted through the first analyte, and a control circuit configured to calculate a concentration of tetrahydrocannabinol in the first analyte based at least in part on the first light.. .
Engineered Medical Technologies

Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitvity in the treatment of a brain tumour

The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (thc) and/or cannabidiol (cbd).
Otsuka Pharmaceutical Co. Limited

Alternative solutions for the administration of cannabis derived botanical products

Compositions comprising: (a) at least one polyvinylpyrrolidone/vinyl acetate copolymer that forms an open matrix network; and (b) at least one ingredient tetrahydrocannabinol and cannabidiol present within the open matrix network.. .

Method for making coffee products containing cannabis ingredients

The present disclosure is directed to methods of making a coffee products containing cannabinoids that are extracted from cannabis plant. According to one embodiment, the method includes the steps of (a) extracting cannabinoids from cannabis plant; and (b) admixing the cannabinoids into a coffee product.
Imbue Llc

Articles and methods for rapid thc detection

This disclosure describes articles for detecting thc in a saliva sample and methods of using the articles. Generally, the articles include a detection zone that generates a detectable signal that allows one to determine whether the sample contains Δ-9-tetrahydrocannabinol.
Thcer Llc

Cannabinod formulation for the sedation of a human or animal

A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery means which doses the recipient with the formulation resulting in a tetrahydrocannabinol blood level of above at least approximately 1-250 milligrams per milliliter of whole blood for incapacitation, or at least approximately 250-500 milligrams per milliliter of whole blood immobilization, and below a dosage which causes irreparable harm to or the death of the recipient. Providing a delivery means to induce an incapacitating or immobilizing dose at a distance.

Mixtures of cannabinoid compounds, and production and use thereof

Furthermore, corresponding pharmaceutical formulations, cosmetic preparations and foodstuff and/or gourmet or snack preparations fit for consumption as well as a method for the manufacture of delta-9-tetrahydrocannabinol are described.. .

Anti-tumoural effects of cannabinoid combinations

The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (thc) and cannabidiol (cbd), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (gbm)..
Otsuka Pharmaceutical Co., Limited

Cannabis drug detection device

A system for collecting cannabis and the psychoactive component tetrahydrocannabinol from a sample of exhaled breath is disclosed. Single or multiple exhaled breaths are conditioned by removing contaminants, and regulating flow rate and/or pressure to collect a sample of tetrahydrocannabinol for timely local or remote analysis.
Cannabix Breathalyzer Inc.

System and determining the concentration of tetrahydrocannabinol

The present describes a system and method for determining the concentration of tetrahydrocannabinol (thc) including a tray comprising a first analyte including an infusion of a solvent and cannabis, a light emitting element configured to illuminate the first analyte, a light receiving element configured to receive a first light transmitted through the first analyte, and a control circuit configured to calculate a concentration of tetrahydrocannabinol in the first analyte based at least in part on the first light.. .
Engineered Medical Technologies

Topical treatments incorporating cannabis sp. derived botanical drug product

A topical formulation comprising a cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.. .

Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

Described herein are Δ9-thc prodrugs, methods of making Δ9-thc prodrugs, formulations comprising Δ9-thc prodrugs and methods of using Δ9-thc. One embodiment described herein relates to the transdermal administration of a Δ9-thc prodrug for treating and preventing diseases and/or disorders..
Zynerba Pharmaceuticals, Inc.

Ultrapure tetrahydrocannabinol-11-oic acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceutics Inc.

Cannabis plant isolate comprising delta-9-tetrahydrocannabinol and a preparing such an isolate

The present invention relates to a method for preparing a cannabis plant Δ9-tetrahydrocannabinol isolate from a crude solvent extract of cannabis plant material. The invention relates further to a cannabis plant thc isolate comprising Δ9-tetrahydrocannabinol, cannabinol (cbn) and/or cannabidiol (cbd) and to a pharmaceutical composition comprising the cannabis plant thc isolate..
Echo Pharmaceuticals B.v.

Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol

Methods for making trans-(−)-Δ9-tetrahydrocannabinoi and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinoi composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinoi composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol.
Svc Pharma Lp

Topical treatments incorporating cannabis sp. derived botanical drug product

A topical formulation comprising a cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.. .

Composition with pharmacological effect for vaporizing and method

A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor.

Plant extract from low-thc cannabis for the treatment of disease

The present invention relates to a plant extract from a low-tetrahydrocannabinol (thc) variety of cannabis sativa subsp. Sativa for the treatment of disease.

Oral dosage form of tetrahydrocannabinol and a avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery

An oral dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts; and (b) an oily medium consisting of: (i) about 15 to 85 wt % of one or more triglycerides formed from long chain fatty having from c13 to c24 carbon atoms; (ii) about 15 to 85 wt % of one or more mixed glycerides formed from long chain fatty having from c13 to c24 carbon atoms; and (iii) one or more free fatty acids formed from un-esterified long chain fatty acids having from c13 to c24 carbon atoms; and (c) about 10 to 70 wt % of a surfactant which promotes self-emulsification..

Phytocannabinoids for use in the treatment of breast cancer

The present invention relates to phytocannabinoids for use in the treatment of a breast cancer. In a first embodiment the invention relates to an oral presentation of tetrahydrocannabinol (thc) for use in the treatment of aggressive breast cancer, characterised by overexpression of the her2 gene.

Pharmaceutical composition comprising cannabinoids having reduced psychoactivity through the combination of cbd and non-decarboxylated thc

The present invention relates to a pharmaceutical composition comprising non-decarboxylated Δ9 tetrahydrocannabinol (thc), cannabidiol (cbd), and at least one small molecule selected from citric acid, ascorbic acid, citrus essential oil(s), lecithin, one or more sugar(s), resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of thc and/or cbd. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the cannabinoid cb1 and/or cb2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof..

Anti-tumoural effects of cannabinoid combinations

The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (thc) and cannabidiol (cbd), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (gbm)..

Cannabis plant named 'avidekel'

The disclosure relates to a new and distinct cultivar of cannabis sativa plant named ‘avidekel’, characterized by a high amount of cannabidiol (cbd) (16.3%) and a very low amount of tetrahydrocannabinol (thc, 0.8%).. .

Process for producing an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material, and cannabis extracts

The invention relates to a method for producing an extract from cannabis plant matter, containing tetrahydrocannabinol, cannabidiol and optionally the carboxylic acids thereof. According to said method, the dried pint matter is ground and subjected to a co2 extraction and the primary extract obtained is separated.

Cannabis plant named midnight

The disclosure relates to a new and distinct cannabis sativa l. Plant named ‘midnight’, having an almost equal ratio of cannabidiol (cbd) concentration to tetrahydrocannabinol (thc) concentration, (e.g., substantially close to 1), as illustrated and described herein..

Cannabis plant named erez

The disclosure relates to a new and distinct cultivar of cannabis sativa plant named ‘erez’, characterized by a high amount of cannabidiol (cbd) (>16%) and a higher amount of tetrahydrocannabinol (thc, ˜23%).. .

A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd)

This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy.

Phytocannabinoids for use in the treatment of cancer

The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases.

Smokeless thc and administration method thereof

A pharmaceutical composition and administration apparatus includes a portable powered vaporizer with a mouthpiece, smokeless vaporizing element, and a removable chamber. The chamber contains a composition comprising tetrahydrocannabinol (thc), cannabidiol (cbd), fcc grade ethanol, flavoring, pharmaceutical grade nicotine, usp grade aqueous glycerine, usp/ep grade propylene glycol, and usp grade vegetable glycerine.



Tetrahydrocannabinol topics:
  • Tetrahydrocannabinol
  • Cannabinoids
  • Cannabinoid
  • Cannabidiol
  • Carisoprodol
  • Buprenorphine
  • Butalbital
  • Benzodiazepine
  • Chromatograph
  • Tandem Mass Spectrometry
  • Meprobamate
  • Pain Medications
  • Spectrometry
  • Benzodiazepines
  • Mass Spectrometry


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Tetrahydrocannabinol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Tetrahydrocannabinol with additional patents listed. Browse our RSS directory or Search for other possible listings.


    4.2684

    file didn't exist7821

    479888 - 0 - 139